EXICURE, INC. (XCUR): Nasdaq/NYSE listing notice — Exicure receives Nasdaq delisting notice for audit committee non-compliance; KPMG resigns as auditor

EXICURE, INC.

Nasdaq notified Exicure on May 10, 2023 of non-compliance with audit committee independence rule due to resignation of director Hyukku Lee effective May 3, 2023.
Cure period ends at earlier of 2023 annual meeting or May 3, 2024; company must comply by Oct 30, 2023 if annual meeting before that date.
KPMG resigned as independent auditor on May 8, 2023; no disagreements or reportable events, but prior reports included going concern emphasis.
Company is searching for a qualified independent director to add to board and audit committee to cure deficiency.

item 3.01 item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

KPMG LLP resigned as auditor of EXICURE, INC..

Action: resignation
Auditor: KPMG LLP

Exact text from the filing

(a) Resignation of Independent Registered Public Accounting Firm On May 8, 2023, KPMG LLP (“ KPMG ”) resigned as the independent registered public accounting firm of the Company and subsidiary, effective immediately.

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

EXICURE, INC. received a nasdaq noncompliance notice notice regarding audit committee (rules 5605, 5605(c)(4)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: audit committee
Rules: 5605, 5605(c)(4)

Exact text from the filing

May 10, 2023, Exicure, Inc. (the “ Company ”) received notice from The Nasdaq Stock Market LLC (“ Nasdaq ”) that the Company is no longer in compliance with Nasdaq’s audit committee requirements as set forth in Nasdaq Listing Rule 5605 as a result of the previously disclosed resignation of Hyukku Lee, effective May 3, 2023 . Nasdaq Rule 5605 requires the audit committee of the board of directors to be comprised of at least three independent directors (the “ Listing Requirement for Audit Committee ”). Pursuant to Nasdaq Listing Rule 5605(c)(4), the Company is entitled to a cure period to regain

View on SEC.gov

6 auditor changes filed in the last 30 days. Browse all auditor changes →

EXICURE, INC. filing history →

Source: SEC EDGAR

accession 0001698530-23-000047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.